Table 1.

Correlation of NCAPH, AGGF1 and FOXC2 with Clinicopathologic Factors in 153 Patients with SOC

Variable	Cases	NCAPH		AGGF1		FOXC2
	n	Positive (%)	P	Positive (%)	P	Positive (%)	P
Age (years)
<53	76	49(63.6%)	0.740	49(63.6%)	0.494	40(51.9%)	0.747
≥53	77	46(60.5%)		53(69.7%)		42(55.3%)
Diameter
< 7cm	95	58(61.1%)	0.864	63(66.3%)	1.000	48(50.5%)	0.404
≥ 7cm	58	37(63.8%)		39(67.2%)		34(58.6%)
Grade
High-grade serous ovarian cancer	69	73(96.9%)	<0.001	74(88.1%)	<0.001	65(77.4%)	<0.001
Low-grade serous ovarian cancer	84	22(31.9%)		28(40.6%)		17(24.6%)
FIGO stage
I–II	63	18(28.6%)	<0.001	26(41.3%)	<0.001	10(15.9%)	<0.001
III–IV	90	77(85.6%)		76(84.4%)		72(80.0%)
LN metastasis
Yes	47	39(83.0%)	0.001	42(89.4%)	<0.001	37(78.7%)	<0.001
No	106	56(52.8%)		60(56.6%)		45(42.5%)
Ascite
Yes	60	33(56.0%)	0.234	36(61.0%)	0.291	27(45.8%)	0.137
No	93	62(66.0%)		66(70.2%)		55(58.5%)
Implantation
Yes	58	47(82.5%)	<0.001	47(82.5%)	0.001	42(73.7%)	<0.001
No	95	48(50.0%)		55(57.3%)		40(41.7%)